Literature DB >> 32460216

A LC-MS/MS method for therapeutic drug monitoring of sorafenib, regorafenib and their active metabolites in patients with hepatocellular carcinoma.

Valentina Iacuzzi1, Martina Zanchetta2, Sara Gagno1, Ariana Soledad Poetto3, Marco Orleni1, Elena Marangon1, Michela Guardascione1, Luisa Foltran4, Bianca Posocco5, Giuseppe Toffoli1.   

Abstract

A liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed and validated for the simultaneous quantification of sorafenib (SORA), its N-oxide active metabolite and of regorafenib (REGO) and its two active metabolites regorafenib N-oxide and N-desmethyl regorafenib N-oxide in hepatocellular carcinoma patients' plasma. A proper analytes' separation was obtained with Synergi Fusion RP column (4 μm, 80 Å, 50 × 2.0 mm) using a gradient elution of 10 mM ammonium acetate with 0.1% formic acid (mobile phase A) and methanol:isopropanol (90:10, v/v, mobile phase B) containing 0.1% formic acid. The analysis was then performed by electrospray ionization in negative mode coupled with a triple quadrupole mass spectrometry, API 4000QT, monitoring two transitions for each analyte, one for the quantification and the other for confirmation. The method could be easily applied to the clinical practice thanks to the short run (7 min), the low amount of patient plasma necessary for the analysis (5 μL) and the fast sample processing based on protein precipitation. The method was therefore fully validated according to FDA and EMA guidelines. The linearity was assessed (R2≥0.998) over the concentration ranges of 50-8000 ng/mL for SORA and REGO, and 30-4000 ng/mL for their metabolites, that appropriately cover the therapeutic plasma concentrations. The presented method also showed adequate results in terms of intra- and inter-day accuracy and precision (CV ≤ 7.2% and accuracy between 89.4% and 108.8%), recovery (≥85.5%), sensitivity, analytes stability under various conditions and the absence of the matrix effect. Once the validation was successfully completed, the method was applied to perform the Cmin quantification of SORA, REGO and their metabolites in 54 plasma samples collected from patients enrolled in a clinical study ongoing at the National Cancer Institute of Aviano.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Hepatocellular carcinoma; LC–MS/MS; Regorafenib; Sorafenib; Therapeutic drug monitoring

Mesh:

Substances:

Year:  2020        PMID: 32460216     DOI: 10.1016/j.jpba.2020.113358

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  3 in total

1.  Rapid Determination of 9 Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma in Human Plasma by QuEChERS-UPLC-MS/MS.

Authors:  Wen Jiang; Tingting Zhao; Xiaolan Zhen; Chengcheng Jin; Hui Li; Jing Ha
Journal:  Front Pharmacol       Date:  2022-06-21       Impact factor: 5.988

2.  Development of UPLC-MS/MS Method to Study the Pharmacokinetic Interaction between Sorafenib and Dapagliflozin in Rats.

Authors:  Xueru He; Ying Li; Yinling Ma; Yuhao Fu; Xuejiao Xun; Yanjun Cui; Zhanjun Dong
Journal:  Molecules       Date:  2022-09-21       Impact factor: 4.927

3.  Direct analysis in real time-mass spectrometry for rapid quantification of five anti-arrhythmic drugs in human serum: application to therapeutic drug monitoring.

Authors:  Yuzhou Gui; Youli Lu; Shuijun Li; Mengqi Zhang; Xiaokun Duan; Charles C Liu; Jingying Jia; Gangyi Liu
Journal:  Sci Rep       Date:  2020-09-23       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.